ArticleCureus2026
A Neonatal Salt-Wasting Crisis Mimicking Congenital Adrenal Hyperplasia: A Case of Transient Pseudohypoaldosteronism.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Salt-losing crisis in the neonate is a life-threatening event manifested by hyponatremia, hyperkalemia, and metabolic acidosis. Whilst this biochemical finding is classically seen in congenital adrenal hyperplasia (CAH), conditions of aldosterone action, such as pseudohypoaldosteronism (PHA), can also present with these findings but require different care. A four-week-old term male infant is described who was brought in with vomiting, lethargy, and anuria. At the time of admission, he was in shock with marked hyponatremia (119 mmol/L), life-threatening hyperkalemia (9.8 mmol/L), metabolic acidosis, and acute kidney injury (AKI). He needed resuscitation, treatment of hyperkalemia, and admission to pediatric intensive care. CAH was considered at the beginning, but newborn mass screening for 17-hydroxyprogesterone was normal, and serum cortisol before steroid therapy was adequate, so primary adrenal failure may be ruled out. Electrolytes and renal function returned promptly to normal after volume repletion, and the patient passed into a polyuric recovery. The clinical course, including rapid resolution of PHA, was consistent with transient (secondary) PHA related to severe volume depletion and prerenal AKI, resulting in temporary renal tubular resistance to aldosterone. This case illustrates the necessity to differentiate secondary PHA from CAH in neonates presenting with salt loss crises, since early recognition spares lifelong unnecessary steroid exposure and directs appropriate supportive care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.